Lunai Bioworks completed a $20 million preferred equity issuance to acquire intellectual property that enhances its central nervous system (CNS) platform with new drug delivery technologies targeting the blood-brain barrier. This acquisition supports Alzheimer's and other neurological disease treatments by enabling therapies to better reach the brain, including nose-to-brain and BBB-crossing delivery methods. The expanded platform also facilitates combination therapies, aligns with AI-driven patient stratification, and opens regulatory and partnership opportunities. This move strengthens Lunai's position in CNS drug development and biodefense applications, aiming for more effective and targeted treatments.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
